Proshares UltraPro NASDAQ Biotechnology
UBIO
UBIO was delisted on the 27th of March, 2020.
7 hedge funds and large institutions have $1.43M invested in Proshares UltraPro NASDAQ Biotechnology in 2019 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
5,800% more call options, than puts
Call options by funds: $236K | Put options by funds: $4K
0% more funds holding
Funds holding: 7 → 7 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
15% less capital invested
Capital invested by funds: $1.68M → $1.43M (-$255K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$369K |
| 2 |
EWA
Exencial Wealth Advisors
Oklahoma City,
Oklahoma
|
+$202K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$5.11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.14M |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$341K |
| 3 |
VF
Virtu Financial
New York
|
-$105K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $850K | +$369K | +13,001 | +81% |
|
|
VF
2
Virtu Financial
New York
| $244K | -$105K | -3,683 | -31% |
|
|
EWA
3
Exencial Wealth Advisors
Oklahoma City,
Oklahoma
| $209K | +$202K | +7,125 | New |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $72K | -$341K | -12,019 | -83% |
|
5
Morgan Stanley
New York
| $24K | – | – | – |
|
|
LTFS
6
Ladenburg Thalmann Financial Services
Miami,
Florida
| $21K | – | – | – |
|
|
7
Simplex Trading
Chicago,
Illinois
| $9K | +$5.11K | +180 | +133% |
|
|
8
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$1.14M | -40,030 | Closed |
|
UBIO Hedge Fund Activity: Q1 2019 in Review
7 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Proshares UltraPro NASDAQ Biotechnology (UBIO) for Q1 2019, worth a combined $1.43M — down 15% from $1.68M a quarter earlier.
Fund positioning in UBIO was balanced in Q1 2019: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 2 trimmed.
The largest buyer was Jane Street, adding an estimated $369K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $1.14M sold.
- 7 institutional investors held Proshares UltraPro NASDAQ Biotechnology (UBIO) as of Q1 2019, unchanged from Q4 2018.
- Funds reported $1.43M of Proshares UltraPro NASDAQ Biotechnology stock for Q1 2019, down 15% quarter-over-quarter.
- 1 fund opened new Proshares UltraPro NASDAQ Biotechnology positions in Q1 2019 and 1 closed out, a net change of 0 holders.
- The largest Proshares UltraPro NASDAQ Biotechnology buyer in Q1 2019 was Jane Street, an estimated $369K added.
- The largest Proshares UltraPro NASDAQ Biotechnology seller in Q1 2019 was Susquehanna International Group, an estimated $1.14M sold.
Based on aggregated 13F filings for Q1 2019.